About: Repositioning of pentoxifylline as an immunomodulator and regulator of the renin-angiotensin system in the treatment of COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Repositioning of pentoxifylline as an immunomodulator and regulator of the renin-angiotensin system in the treatment of COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Repositioning of pentoxifylline as an immunomodulator and regulator of the renin-angiotensin system in the treatment of COVID-19
Creator	Alderete, Chávez, Jaime Loza-Mejía, Jaime Ma, Loza-Mejía Maldonado, Valente Phd, Alderete
Source	Elsevier; Medline; PMC
abstract	Pentoxifylline (PTX) is a phosphodiesterase inhibitor that increases cyclic adenosine monophosphate levels, which in turn activate protein kinase, leading to a reduction in the synthesis of proinflammatory cytokines to ultimately influence the renin-angiotensin system (RAS) in vitro by inhibiting angiotensin 1 receptor (AT1R) expression. The rheological, anti-inflammatory, and renin-angiotensin axis properties of PTX highlight this drug as a therapeutic treatment alternative for patients with COVID-19 by helping reduce the production of the inflammatory cytokines without deleterious effects on the immune system to delay viral clearance. Moreover, PTX can restore the balance of the immune response, reduce damage to the endothelium and alveolar epithelial cells, improve circulation, and prevent microvascular thrombosis. There is further evidence that PTX can improve ventilatory parameters. Therefore, we propose repositioning PTX in the treatment of COVID-19. The main advantage of repositioning PTX is that it is an affordable drug that is already available worldwide with an established safety profile, further offering the possibility of immediately analysing the result of its use and associated success rates. Another advantage is that PTX selectively reduces the concentration of TNF-α mRNA in cells, which, in the case of an acute infectious state such as COVID-19, would seem to offer a more strategic approach.
has issue date	2020-06-09(xsd:dateTime)
bibo:doi	10.1016/j.mehy.2020.109988
bibo:pmid	32540603
has license	no-cc
sha1sum (hex)	0c19d94db30489a2369209a1dbea3acf274992ba
schema:url	https://doi.org/10.1016/j.mehy.2020.109988
resource representing a document's title	Repositioning of pentoxifylline as an immunomodulator and regulator of the renin-angiotensin system in the treatment of COVID-19
has PubMed Central identifier	PMC7282759
has PubMed identifier	32540603
schema:publication	Med Hypotheses
resource representing a document's body	covid:0c19d94db30489a2369209a1dbea3acf274992ba#body_text
is schema:about of	named entity 'protein kinase' named entity 'PTX' named entity 'delay' named entity 'epithelial cells' named entity 'patients' named entity 'selectively' named entity 'COVID-19' named entity 'receptor' named entity 'rheological' named entity 'success' named entity 'therapeutic' named entity 'activate' named entity 'production' named entity 'RAS' named entity 'TNF' named entity 'receptor' named entity 'PTX' named entity 'COVID-19' named entity 'renin-angiotensin' named entity 'PTX' named entity 'COVID' named entity 'COVID' named entity 'pentoxifylline' named entity 'lungs' named entity 'hemophagocytic syndrome' named entity 'plasma' named entity 'SARS-CoV' named entity 'endothelial' named entity 'cAMP' named entity 'COVID' named entity 'alveolar epithelial cells' named entity 'Th17 cells' named entity 'infection' named entity 'arteries' named entity 'IL-1' named entity 'type 2 diabetes mellitus' named entity 'fibrotic' named entity 'receptor' named entity 'ACE2' named entity 'SARS-CoV-2' named entity 'anti-inflammatory' named entity 'CD4+ T cells' named entity 'cell death' named entity 'tissue injury' named entity 'rheological' named entity 'IFN' named entity 'ALI' named entity 'cAMP' named entity 'superoxide' named entity 'pathological conditions' named entity 'angiotensin' named entity 'blood pressure' named entity 'RAS' named entity 'AT1R' named entity 'clinical guidelines' named entity 'blood flow' named entity 'inflammation' named entity 'chemokines' named entity 'ACE' named entity 'immunosuppression' named entity 'perfusion' named entity 'ARDS' named entity 'Italy' named entity 'immune response' named entity 'CD8+ T cells' named entity 'randomized controlled clinical trial' named entity 'negative regulator' named entity 'immune response' named entity 'lymphopenia' named entity 'diabetic nephropathy' named entity 'ground-glass opacities' named entity 'hypoxemia' named entity 'genetic analysis' named entity 'immune response' named entity 'COVID' named entity 'TNF-α'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software